Alosetron Confirms 5-HT₃ Modulation Efficacy
Clinical data demonstrates significant urgency reduction with 5-HT3 modulation, but labeling restrictions and safety concerns limit its use in severe IBS-D
STX-101 Delivers Balanced 5-HT₃ Signaling
Precision Therapy Backed by a Digital Support Structure
Real-time patient engagement and clinician oversight combine with targeted 5-HT₃ modulation delivers a “trial-in-a-product” therapeutic
Supportive Trial Structure Demonstrates Clinical Benefit
